vs

Side-by-side financial comparison of Blaize Holdings, Inc. (BZAI) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $23.8M, roughly 1.5× Blaize Holdings, Inc.). Blaize Holdings, Inc. runs the higher net margin — -13.9% vs -304.2%, a 290.4% gap on every dollar of revenue. On growth, Blaize Holdings, Inc. posted the faster year-over-year revenue change (2377500.0% vs 681.7%). Blaize Holdings, Inc. produced more free cash flow last quarter ($-16.5M vs $-47.3M).

Blaize Holdings, Inc. is a technology company specializing in edge artificial intelligence computing solutions. It designs energy-efficient AI processors, low-latency inference software stacks, and end-to-end edge AI development tools, serving key segments including autonomous driving, industrial automation, smart cities, and edge healthcare monitoring.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BZAI vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.5× larger
RXRX
$35.5M
$23.8M
BZAI
Growing faster (revenue YoY)
BZAI
BZAI
+2376818.3% gap
BZAI
2377500.0%
681.7%
RXRX
Higher net margin
BZAI
BZAI
290.4% more per $
BZAI
-13.9%
-304.2%
RXRX
More free cash flow
BZAI
BZAI
$30.8M more FCF
BZAI
$-16.5M
$-47.3M
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BZAI
BZAI
RXRX
RXRX
Revenue
$23.8M
$35.5M
Net Profit
$-3.3M
$-108.1M
Gross Margin
10.8%
59.8%
Operating Margin
-89.8%
-304.8%
Net Margin
-13.9%
-304.2%
Revenue YoY
2377500.0%
681.7%
Net Profit YoY
50.7%
39.6%
EPS (diluted)
$0.16
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BZAI
BZAI
RXRX
RXRX
Q4 25
$23.8M
$35.5M
Q3 25
$11.9M
$5.2M
Q2 25
$19.2M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$14.4M
Q1 24
$13.8M
Net Profit
BZAI
BZAI
RXRX
RXRX
Q4 25
$-3.3M
$-108.1M
Q3 25
$-26.3M
$-162.3M
Q2 25
$-171.9M
Q1 25
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$-97.5M
Q1 24
$-91.4M
Gross Margin
BZAI
BZAI
RXRX
RXRX
Q4 25
10.8%
59.8%
Q3 25
15.0%
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
BZAI
BZAI
RXRX
RXRX
Q4 25
-89.8%
-304.8%
Q3 25
-190.3%
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
BZAI
BZAI
RXRX
RXRX
Q4 25
-13.9%
-304.2%
Q3 25
-221.3%
-3135.3%
Q2 25
-894.2%
Q1 25
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
-676.6%
Q1 24
-662.4%
EPS (diluted)
BZAI
BZAI
RXRX
RXRX
Q4 25
$0.16
$-0.17
Q3 25
$-0.25
$-0.36
Q2 25
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BZAI
BZAI
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$45.8M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$39.0M
$1.1B
Total Assets
$102.2M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BZAI
BZAI
RXRX
RXRX
Q4 25
$45.8M
$743.3M
Q3 25
$24.0M
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
BZAI
BZAI
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
BZAI
BZAI
RXRX
RXRX
Q4 25
$39.0M
$1.1B
Q3 25
$1.3M
$1.0B
Q2 25
$919.1M
Q1 25
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$584.4M
Q1 24
$401.2M
Total Assets
BZAI
BZAI
RXRX
RXRX
Q4 25
$102.2M
$1.5B
Q3 25
$60.9M
$1.4B
Q2 25
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$775.9M
Q1 24
$557.8M
Debt / Equity
BZAI
BZAI
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BZAI
BZAI
RXRX
RXRX
Operating Cash FlowLast quarter
$-16.5M
$-46.1M
Free Cash FlowOCF − Capex
$-16.5M
$-47.3M
FCF MarginFCF / Revenue
-69.6%
-133.1%
Capex IntensityCapex / Revenue
0.3%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BZAI
BZAI
RXRX
RXRX
Q4 25
$-16.5M
$-46.1M
Q3 25
$-24.9M
$-117.4M
Q2 25
$-76.4M
Q1 25
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
BZAI
BZAI
RXRX
RXRX
Q4 25
$-16.5M
$-47.3M
Q3 25
$-24.9M
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
BZAI
BZAI
RXRX
RXRX
Q4 25
-69.6%
-133.1%
Q3 25
-210.2%
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
BZAI
BZAI
RXRX
RXRX
Q4 25
0.3%
3.5%
Q3 25
0.2%
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons